I agree that this site is using cookies. You can find further informations here.
X
Broedl, Uli C
132  results:
Search for persons X
?
1

Inclusion and diversity in clinical trials: Actionable step..:

Kelsey, Michelle D. ; Patrick-Lake, Bray ; Abdulai, Raolat...
Contemporary Clinical Trials.  116 (2022)  - p. 106740 , 2022
Link: https://doi.org/10.1016/..
 
?
2

Leveraging Blockchain Technology for Informed Consent Proce..:

Mak, Baldwin C. ; Addeman, Bryan T. ; Chen, Jia...
Blockchain in Healthcare Today.  , 2021
Link: https://doi.org/10.30953..
 
?
3

Predictions for Blockchain in 2020:

Mathew, George T. ; Porto, Dennis A. ; Ribitzky, Ron...
Blockchain in Healthcare Today.  3 (2020)  - p. , 2020
Link: https://doi.org/10.30953..
 
?
4

Rationale, design, and baseline characteristics of the CArd..:

Rosenstock, Julio ; Perkovic, Vlado ; Alexander, John H....
Cardiovascular Diabetology.  17 (2018)  1 - p. , 2018
Link: https://doi.org/10.1186/..
 
?
5

Are the Cardiovascular (CV) Risk Reductions Seen with Empag..:

Broedl, Uli C. ; Fitchett, David ; Coleman, Ruth L....
Canadian Journal of Diabetes.  41 (2017)  5 - p. S5 , 2017
Link: https://doi.org/10.1016/..
 
?
6

The effect of empagliflozin on muscle sympathetic nerve act..:

Jordan, Jens ; Tank, Jens ; Heusser, Karsten...
Journal of the American Society of Hypertension.  11 (2017)  9 - p. 604-612 , 2017
Link: https://doi.org/10.1016/..
 
?
7

Influence of common polymorphisms in the SLC5A2 gene on met..:

Zimdahl, Heike ; Haupt, Axel ; Brendel, Michael...
Pharmacogenetics and Genomics.  27 (2017)  4 - p. 135-142 , 2017
Link: https://doi.org/10.1097/..
 
?
8

Erratum to: Characterisation of glomerular haemodynamic res..:

Škrtić, Marko ; Yang, Gary K. ; Perkins, Bruce A....
Diabetologia.  60 (2017)  6 - p. 1159-1160 , 2017
Link: https://doi.org/10.1007/..
 
?
9

Effect of Empagliflozin on Mortality and Causes of Death in..:

Fitchett, David ; Inzucchi, Silvio ; Lachin, John...
Canadian Journal of Diabetes.  40 (2016)  5 - p. S4-S5 , 2016
Link: https://doi.org/10.1016/..
 
?
10

Acute Pharmacodynamic Effects of Empagliflozin With and Wit..:

Heise, Tim ; Jordan, Jens ; Wanner, Christoph...
Clinical Therapeutics.  38 (2016)  10 - p. 2248-2264.e5 , 2016
Link: https://doi.org/10.1016/..
 
?
11

Population Pharmacokinetics and Exposure–Response (Efficacy..:

Baron, Kyle T. ; Macha, Sreeraj ; Broedl, Uli C....
Diabetes Therapy.  7 (2016)  3 - p. 455-471 , 2016
Link: https://doi.org/10.1007/..
 
?
12

Safety and Tolerability of Empagliflozin in Patients with T..:

Kohler, Sven ; Salsali, Afshin ; Hantel, Stefan...
Clinical Therapeutics.  38 (2016)  6 - p. 1299-1313 , 2016
Link: https://doi.org/10.1016/..
 
?
13

Heart failure outcomes with empagliflozin in patients with ..:

Fitchett, David ; Zinman, Bernard ; Wanner, Christoph...
European Heart Journal.  37 (2016)  19 - p. 1526-1534 , 2016
Link: https://doi.org/10.1093/..
 
?
14

Linagliptin as add‐on to empagliflozin and metformin in pat..:

Tinahones, Francisco J. ; Gallwitz, Baptist ; Nordaby, Matias...
Diabetes, Obesity and Metabolism.  19 (2016)  2 - p. 266-274 , 2016
Link: https://doi.org/10.1111/..
 
?
15

Pharmacodynamic Effects of Single and Multiple Doses of Emp..:

Heise, Tim ; Jordan, Jens ; Wanner, Christoph...
Clinical Therapeutics.  38 (2016)  10 - p. 2265-2276 , 2016
Link: https://doi.org/10.1016/..
 
1-15